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ABSTRACT: Fireﬂy luciferase is homologous to fatty
acyl-CoA synthetases. We hypothesized that the ﬁreﬂy
luciferase substrate D-luciferin and its analogs are fatty acid
mimics that are ideally suited to probe the chemistry of
enzymes that release fatty acid products. Here, we
synthesized luciferin amides and found that these
molecules are hydrolyzed to substrates for ﬁreﬂy luciferase
by the enzyme fatty acid amide hydrolase (FAAH). In the
presence of luciferase, these molecules enable highly
sensitive and selective bioluminescent detection of
FAAH activity in vitro, in live cells, and in vivo. The
potency and tissue distribution of FAAH inhibitors can be
imaged in live mice, and luciferin amides serve as
exemplary reagents for greatly improved bioluminescence
imaging in FAAH-expressing tissues such as the brain.
Fireﬂy luciferase is best known for its light emission chemistrywith D-luciferin, but it is also a long-chain fatty acyl-CoA
synthetase (ACSL) that can bind fatty acid substrates such as
arachidonic acid (Figure 1).1 Conversely, we have recently
shown that an ACSL from the fruit ﬂy Drosophila melanogaster is
a latent luciferase that can emit light with a synthetic luciferin.2 In
both cases, adenylation of a carboxylic acid is the ﬁrst step in
catalysis. Furthermore, both enzymes can bind fatty acids ranging
from octanoic acid to arachidonic acid, suggesting that D-luciferin
and aminoluciferin analogs3−5 are acting as fatty acid mimics.
Based in part on this observation, we hypothesized that luciferins
are ideally suited to probe the chemistry of enzymes that release
fatty acid products.
Fatty acid amide hydrolase (FAAH) is a serine hydrolase that
limits the lifetime and sphere of action of fatty acid amide second
messengers by hydrolysis to their corresponding fatty acids
(Figure 1).6,7 Most notably, arachidonoyl ethanolamine
(anandamide) is a locally generated agonist for the cannabinoid
receptor CB1. Inhibition of FAAH prolongs the action of
anandamide and is therefore an attractive drug target for the
treatment of pain, anxiety, and cannabinoid dependence.6 Many
FAAH inhibitors are being developed as potential therapeutics,
and there is great interest in detecting FAAH activity in vivo.8
Current techniques to assay FAAH inhibitors in mice primarily
require sacriﬁcing the mouse, homogenizing the tissues, adding
radioactive lipid substrates, and HPLC analysis of the products.9
This places large demands on time and quantities of mice
required to evaluate inhibitors and furthermore cannot give
longitudinal data from the same animal. Some inroads have been
made with PET imaging probes for FAAH, but these are
specialized and expensive tools with low throughput and signal-
to-noise that lack the speciﬁcity for whole-body imaging.8
FAAH readily accepts a wide range of saturated and
unsaturated fatty acid amides in addition to anandamide7,10
and has been shown to hydrolyze ethanolamides, primary
amides, andmethyl amides.7,10,11We therefore hypothesized that
FAAH could hydrolyze luciferin amides to their respective
carboxylates, resulting in the formation of a luminogenic
luciferase substrate (Figure 1). Here we show that luciferin
amides allow exquisitely selective and sensitive imaging of
endogenous FAAH activity in live cells and in live mice. FAAH is
both necessary and suﬃcient for bioluminescence to occur and is
the only enzyme activating these probes. The performance of
FAAH inhibitors can be imaged in live mice, and inhibitors that
cross the blood-brain barrier can be readily distinguished from
those that cannot. Moreover, the amount of luciferin amide
probe needed to perform this imaging is >1000-fold lower than
typical D-luciferin imaging conditions but nonetheless improves
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Figure 1. (A) Fireﬂy luciferase catalyzes light emission from D-luciferin.
(B) Fireﬂy luciferase is also a fatty acyl-CoA synthetase. (C) FAAH
cleaves anandamide to arachidonic acid. (D) Luciferin amides could
allow bioluminescence imaging of FAAH activity.
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overall signal from the brain. Thus, luciferin amides also excel at
delivering luciferins into FAAH-expressing cells and tissues.
To test our initial hypothesis, we synthesized four luciferin
amides (Figure 1) by the condensation of electrophilic nitriles3,5
with a D-cysteine amide (see Supporting Information). Without a
free carboxylate, these luciferin analogs are not light-emitting
substrates for puriﬁed ﬁreﬂy luciferase (Figures 2 and S1).
Pretreatment of the luciferin amides with recombinant rat
FAAH12 restores luminescent activity and could be speciﬁcally
blocked by incubation with FAAH inhibitors such as PF3845
(Figures 2 and S1).13 The presence of FAAH or FAAH inhibitors
has no eﬀect on light emitted from the parent luciferins (Figures
2 and S1). Thus, luciferin amides can be used to detect FAAH
activity and inhibition in vitro.
We next sought to determine whether luciferin amides were
speciﬁc to FAAH and sensitive enough to enable the detection of
FAAH activity in live cells. Chinese hamster ovary (CHO) cells
are known to express FAAH,14 an integral membrane protein,6
but at levels insuﬃcient to detect with ﬂuorescence-based
assays.15 In contrast, treatment of luciferase-expressing CHO
cells with luciferin amides resulted in robust bioluminescence
(Figures 3A and S2). Potentially, in the complex environment of
the cell, luciferin amides could be cleaved by proteases or other
serine hydrolases. However, treatment with PF3845, which
speciﬁcally inhibits FAAH but no other serine hydrolases,13
blocked emission from luciferin amides but had no eﬀect on
luciferase activity in the presence of the parent luciferin (Figure
3A). Furthermore, inhibitors of other serine hydrolases had no
eﬀect, and we evaluated the potency of a wide range of FAAH
inhibitors in the natural context of live cell membranes (Figures
S3 and S4). Lacking an ionized carboxylate, the luciferin amides
also served as excellent luciferin delivery vehicles in these FAAH-
expressing cells, yielding higher bioluminescence signals than
their parent luciferins at concentrations <100 μM (Figure S2).
CycLuc1-methyl amide achieved higher maximal photon ﬂux
than CycLuc1-amide, presumably because uncleaved CycLuc1-
amide can ultimately inhibit luciferase, while CycLuc1-methyl
amide cannot (Figures S2 and S5).
HeLa cells do not express FAAH,16,17 and luciferin amides do
not yield bioluminescence in luciferase-expressing HeLa cells
(Figure 3B). Transfection of HeLa cells with human FAAH
enabled bioluminescence with luciferin amides (Figures 3B and
S2). Speciﬁc inhibition of the transfected FAAH with PF3845
blocked bioluminescence (Figure 3B) and the potency of FAAH
inhibitors could be evaluated in these FAAH-transfected live cells
(Figure S3). FAAH has been shown to cleave some fatty acid
esters,11 and we ﬁnd that it indeed also contributes to the
cleavage of CycLuc1 ethyl ester (Figure S6). However, unlike
CycLuc1 amides, the ethyl ester of CycLuc1 is not exclusively
cleaved by FAAH and is hydrolyzed to CycLuc1 in both CHO
and HeLa cells (Figure S6).
In mice, FAAH is highly expressed in the brain.9 We thus
expected that luciferin amides would result in strong brain
bioluminescence in luciferase-expressing mice if able to access
this tissue. We used adeno-associated virus 9 (AAV9) to express
luciferase only in the brain striatum.18 The amides are less water-
soluble than the parent carboxylates, necessitating a lower
imaging dose. Nonetheless, CycLuc1-amide yielded dramatically
higher photon ﬂux in these mice than the parent luciferin
CycLuc1 or the conventional substrate D-luciferin (Figure 4). A
400-fold lower dose of CycLuc1-amide was markedly superior to
the standard imaging dose of D-luciferin (Figure 4). Even 1000-
fold lower doses yielded higher brain bioluminescence than D-
luciferin (Figure S7).
Figure 2. (A) FAAH inhibitor structures. (B) Photon ﬂux from the
indicated luciferin analog (10 μM) normalized to emission in the
presence of FAAHwith no FAAH inhibitor. The assay was performed in
triplicate and is represented as the mean ± SEM.
Figure 3. (A) Relative photon ﬂux from live luciferase-expressing CHO
cells treated with the indicated luciferins and luciferin amides (125 μM)
in the absence (black bars) or presence (red bars) of the FAAH inhibitor
PF3845. The data are normalized to the uninhibited sample for each
luciferin (black bars). (B) Relative ﬂux from live luciferase-expressing
HeLa cells treated with the same set of substrates after transfection with
empty pcDNA3.1 vector (black bars), pcDNA3.1-hFAAH (blue bars),
or pcDNA3.1-hFAAH and treatment with the FAAH inhibitor PF3845
(red bars). The data are normalized to the uninhibited hFAAH-
transfected sample for each luciferin (blue bars). All assays were
performed in triplicate and are represented as the mean ± SEM.
Journal of the American Chemical Society Communication
DOI: 10.1021/jacs.5b04357
J. Am. Chem. Soc. 2015, 137, 8684−8687
8685
Pretreatment with PF3845 (Figure 2), which has been
demonstrated to inhibit only FAAH in mice,13 completely
blocked brain bioluminescence when using luciferin amides
(Figure S8). Tail-vein injection of AAV9-CMV-luc2 primarily
transduces heart19 and leg muscles (Figure 4), tissues where
FAAH activity has been reported to be absent.9 In these mice,
luciferin amides yielded dramatically lower photon ﬂux than
could be achieved with their parent luciferins (Figure 4). By
contrast, CycLuc1 ethyl ester was on par with equal doses of the
parent luciferin in the heart and leg muscles, but ineﬀective in the
brain (Figure 4). These diﬀerences likely reﬂect the location of
the liberating enzymatic activity and biodistribution of the more
hydrophobic ester.
To visualize FAAH activity throughout the mouse, we next
turned to transgenic mice that express luciferase in all tissues.20
When D-luciferin or CycLuc1 is introduced into these mice, the
weakest light emission is from the head, and bioluminescence is
dominated by superﬁcial tissues (Figures 5 and S9). In marked
contrast, injection of CycLuc1-amide revealed the strongest
bioluminescence signals from the brain and kidneys (Figure 5),
tissues known to have high FAAH activity.9 Ventral bio-
luminescence was less well-deﬁned, which may reﬂect rapid
transit of released luciferin out of FAAH-expressing tissues such
as the liver (Figure S9). Pretreatment of mice with PF3845
completely blocked bioluminescence from luciferin amides in the
brain and in all peripheral tissues (Figures 5, S10, and S11) but
had no eﬀect on bioluminescence from the parent luciferins
(Figure S12). The aminoluciferin amides (Figure 1) readily sense
FAAH activity in vivo (Figure S9), and can be imaged at
extremely low doses (as low as 8 nmol/kg; Figure S13). Although
D-luciferin amide senses FAAH activity in vitro and in live cells, it
works poorly in live mice and cannot sense FAAH activity in the
brain (Figure S9). This is consistent with our contention that the
improved biodistribution properties of aminoluciferins and low
Km values render them superior for use as luminogenic sensors in
vivo.4 Interestingly, CycLuc1-methyl amide did not exhibit an
advantage over CycLuc1-amide in the mouse (Figure S9).
Presumably, inhibition of luciferase by uncleaved luciferin
primary amides is not an issue at the substrate concentrations
achieved in vivo.
Figure 4. CycLuc1-amide compared to D-Luciferin for bioluminescence imaging in live mice expressing luciferase in (A) the brain or (B) the heart and
leg muscles. Quantiﬁcation is represented as the mean ± SEM for n = 3 mice.
Figure 5. (A) Bioluminescence imaging with CycLuc1 or CycLuc1-
amide in ubiquitously expressing transgenic luciferase mice treated with
vehicle only or the indicated FAAH inhibitor. (B) Total ﬂux from the
brain and kidneys quantitated as a function of inhibitor concentration
and normalized to the vehicle-only signal, represented as the mean ±
SEM for n = 3 mice. Data were ﬁt by nonlinear regression to determine
relative IC50 values in the brain (PF3845, 0.14 mg/kg; URB597, 0.40
mg/kg; URB937, ND) and kidneys (PF3845, 0.03 mg/kg; URB597,
0.07 mg/kg; URB937, 0.33 mg/kg).
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Finally, we sought to determine whether luciferin amides could
be used to evaluate the tissue distribution of prospective FAAH
inhibitors, which can have important eﬀects on their eﬃcacy.21
URB937 is a brain-impermeable FAAH inhibitor that diﬀers
from the global FAAH inhibitor URB597 by a single hydroxyl
group (Figure 2).21 Bioluminescence imaging with CycLuc1-
amide conﬁrmed that URB597 inhibits FAAH activity in both
peripheral and brain tissues (Figures 5, S10, and S11), whereas
no inhibition of FAAH activity is detected in the brains of
URB937-treated mice (Figure 5).
Many bioluminescent sensors have been described based on
“caged” pro-luciferins that can release a luciferin upon the action
of an enzyme or reactive small molecule.4,22 The labile moiety is
distinct from the luciferin and often separated by a self-
immolative linker.23 A limitation of this approach is that the
luciferin itself is not contributing to speciﬁc recognition or
selectivity; the best one can hope for is that its presence is
innocuous. Our approach embraces the inherent fatty acid
mimetic properties of luciferin analogs to create sensors for
enzymes that release fatty acids. The power of this approach is
borne out in the exquisite speciﬁcity and sensitivity of luciferin
amides for FAAH even in vivo, simply by replacing an oxygen
atom with nitrogen (Figure 1). Furthermore, we ﬁnd that
luminogenic sensors based on high-aﬃnity, cell-permeable
aminoluciferins perform better in mice than those based on D-
luciferin. As the number of structurally distinct luciferin analogs
grows,4,5 we anticipate there will be additional opportunities to
build sensors based on the inherent properties of the luciferin
itself.
In summary, we have found that luciferin amides are highly
sensitive and selective reporters of FAAH activity. These sensors
readily translate from in vitro assays to live cells to in vivo imaging
to report on the activity of a single enzyme in its natural context.
The bioluminescence approach described herein reveals
otherwise invisible endogenous enzymatic activity in live cells
and mice and more broadly allows imaging of the biodistribution
consequences of subtle modiﬁcations to a prospective
therapeutic inhibitor in vivo (e.g., ability to cross the blood-
brain barrier). Further reﬁnement and modiﬁcation of the
structure of the luciferin4,5 and the scissile bond could potentially
allow extension of this bioluminescence detection approach to
other enzymes.24,25 Finally, luciferin amides are excellent
reagents for increasing the sensitivity of bioluminescence
imaging in FAAH-expressing cells and tissues, such as the
brain, and allow orders of magnitude lower imaging doses than
the natural luciferase substrate.
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